en · de · es · fr · pt
bench-notes.peptides8425.com › Blog › Epitalon Background And Discovery — Worked Examples

Epitalon Background And Discovery — Worked Examples

By Editorial Desk · published 2025-07-29 · last reviewed 2025-08-22 · Blog

epitalon raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-08-22 and is reviewed periodically as new material appears.

Epitalon Background and Discovery

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Epitalon Background and Nomenclature

Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.

The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.

Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.

Epitalon at a glance

PropertyValueNotes
Molecular formulaC14H22N4O9Derived from the four-residue sequence
Molar massAbout 390.35 g/molFree peptide, counter-ion not included
AppearanceWhite to off-white powderLyophilised solid from aqueous solution
Water solubilityFreely solubleShort, polar peptide chain
Common synonymsAEDG; epithaloneCatalogues use the names interchangeably

Structure, Naming and Discovery

Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.

The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.

Related pages on this site

Epitalon Structure and Research Origin

Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.

(TG:@pojiaai)Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.

Epitalon Background And Identification

Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.

Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.

The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.

Identity and Research Background

The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.

Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.

Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.

Notes from published material

=== Location === Catecholamines are produced mainly by the chromaffin cells of the adrenal medulla and the postganglionic fibers of the sympathetic nervous system. Dopamine, which acts as a neurotransmitter in the central nervous system, is largely produced in neuronal cell bodies in two areas of the brainstem: the ventral tegmental area and the substantia nigra, the latter of which contains neuromelanin-pigmented neurons. The similarly neuromelanin-pigmented cell bodies of the locus coeruleus produce norepinephrine. Epinephrine is produced in small groups of neurons in the human brain which express its synthesizing enzyme, phenylethanolamine N-methyltransferase; these neurons project from a nucleus that is adjacent (ventrolateral) to the area postrema and from a nucleus in the dorsal region of the solitary tract.

== The Holocaust == On 6 March 1943, Eva and her parents were transported to the Theresienstadt Ghetto in Terezín, where her father was separated from her and her mother. In Terezín, she worked in agriculture, so she was able to go into the ghetto and managed to make contact with her father. In December 1943, she and her mother were transferred to the Auschwitz concentration camp, where she stayed until June 1944. After six months of horrible conditions at Auschwitz, Eva and her mother were unexpectedly recognized as able to work and were relocated to the Dessauer Ufer camp of the Neuengamme concentration camp in Hamburg, where she experienced better conditions. Her final transport was without her mother to Bergen-Belsen concentration camp in April 1945, which was liberated the same month.

According to Goodrich, both lineages evolved from an earlier stem group, Protosauria ("first lizards") in which he included some animals today considered reptile-like amphibians, as well as early reptiles. In 1956, D.M.S. Watson observed that the first two groups diverged very early in reptilian history, so he divided Goodrich's Protosauria between them. He also reinterpreted Sauropsida and Theropsida to exclude birds and mammals, respectively. Thus his Sauropsida included Procolophonia, Eosuchia, Millerosauria, Chelonia (turtles), Squamata (lizards and snakes), Rhynchocephalia, Crocodilia, "thecodonts" (paraphyletic basal Archosauria), non-avian dinosaurs, pterosaurs, ichthyosaurs, and sauropterygians. In the late 19th century, a number of definitions of Reptilia were offered. The biological traits listed by Lydekker in 1896, for example, include a single occipital condyle, a jaw joint formed by the quadrate and articular bones, and certain characteristics of the vertebrae. The animals singled out by these formulations, the amniotes other than the mammals and the birds, are still those considered reptiles today. The synapsid/sauropsid division supplemented another approach, one that split the reptiles into four subclasses based on the number and position of temporal fenestrae, openings in the sides of the skull behind the eyes. This classification was initiated by Henry Fairfield Osborn and elaborated and made popular by Romer's classic Vertebrate Paleontology. Those four subclasses were:

Sources: en.wikipedia.org

Further detail

== Vulnerabilities == In March 2013, a known issue affecting ColdFusion 8, 9 and 10 left the National Vulnerability Database open to attack. The vulnerability had been identified and a patch released by Adobe for CF9 and CF10 in January. In April 2013, a ColdFusion vulnerability was blamed by Linode for an intrusion into the Linode Manager control panel website. A security bulletin and hotfix for this had been issued by Adobe a week earlier. In May 2013, Adobe identified another critical vulnerability, reportedly already being exploited in the wild, which targets all recent versions of ColdFusion on any servers where the web-based administrator and API have not been locked down. The vulnerability allows unauthorized users to upload malicious scripts and potentially gain full control over the server. A security bulletin and hotfix for this was issued by Adobe 6 days later. In April 2015, Adobe fixed a cross-site scripting (XSS) vulnerability in Adobe ColdFusion 10 before Update 16, and in ColdFusion 11 before Update 5, that allowed remote attackers to inject arbitrary web script or HTML; however, it's exploitable only by users who have authenticated through the administration panel.

== SB == Sb – (s) Antimony (Latin Stibium) SbA - Stibarsen, an alloy of antimony and arsenic SB (i) Sexy Bitch Sexy Bastard Sexy Boy (disambiguation) (s) Solomon Islands (ISO 3166 digram) (i) Special Warfare Boat Operator SBA (i) Santa Barbara Airport Simulation-Based Acquisition Small Business Administration Sovereign Base Area Student bar association SBB – (i) German for the Swiss Federal Railways SBC (i) Sensotronic Brake Control Single-Board Computer Southern Baptist Convention Sun Belt Conference (US college sports) SBCCOM – (p) U.S. Army Soldier and Biological Chemical Command (disbanded 2003) SBCS – (i) Single-Byte Character Set SBCT – (i) Stryker Brigade Combat Team SBD (s) Solomon Islands dollar (ISO 4217 currency code) Silent But Deadly SBP (i) Samahang Basketbol ng Pilipinas (Filipino, "Basketball Federation of the Philippines") U.S. School Breakfast Program Society of Business Practitioners State Bank of Pakistan SBS (i) Special Boat Service Special Broadcasting Service Seoul Broadcasting System SBW (i) Sonny Bill Williams (New Zealand dual-code rugby player)

== Causes == It is mainly unknown what causes sJIA. There have been reports of seasonal fluctuations in the incidence of sJIA in some places but not in others. Although it has frequently been claimed that infectious organisms cause the condition to manifest, microbiologic and virologic analyses are unable to pinpoint a single agent as the cause. Since a negative septic screen is required for the diagnosis, sJIA is not an infectious disease by definition. There is evidence that suggests a genetic predisposition plays a role in the etiology of sJIA.

Sources: en.wikipedia.org

Background from the literature

== GLP-1, GIP, and glucagon receptor triple agonists == Following the discovery of GLP-1/GIP and GLP-1/glucagon dual agonists, it was hoped that a triple agonist would provide additive or synergistic metabolic benefits. A clinical trial of the triple agonist retatrutide found an average 24.2% weight reduction in the highest dosage group after 24 weeks. Another clinical trial of triple agonist UBT-251 also found an average weight reduction of 19.7% after 24 weeks.

== Applications == This chemical similarity can be exploited in cancer, where a protein may mutate into an "always on" (constitutively active) state. A mutation may occur to replace a tyrosine (which needs to be phosphorylated in order to activate the protein) with an aspartic acid (which would not need to be phosphorylated). In a laboratory setting, the use of recombinant proteins to artificially introduce phosphomimetics is a common tool for studying phosphorylation and protein activation. For example, the IRF3 protein must be phosphorylated for its normal activity (transcription of its target genes, like IFNβ), but when serine amino acid residues were mutated to aspartic acid, the activity increased 90-fold. Phosphomimetics are commonly used in a gain of function experiment with respect to phosphorylation. For example, aspartate mutants were successfully used to probe the biological function of the phosphorylation of a threonine residue of a ribosomal protein both in vivo and in vitro to investigate a gain-of-function mutation on a kinase that is related to Parkinson's disease. Phosphomimetics were also used to investigate the therapeutic potential of proteins or peptides. For example, phosphomimetic mutants (using glutamate to mimic serine phosphorylation) have been used to demonstrate that the phosphorylated glycoproteins may have stronger anti-melanoma effects that the wildtype protein.

[M(H2O)n] + L ⇌ [M(H2O)n−1L] + H2O However, since water is in vast excess, the concentration of water is usually assumed to be constant and is omitted from equilibrium constant expressions. Often, the metal and the ligand are in competition for protons. For the equilibrium

==== Human evolution ==== During the long period between one and three million years ago, the Australopithecine (ancestors of modern humans) underwent several evolutionary changes. A long-term climate shift toward drier conditions promoted life changes from sedentary forest-dwelling with a primarily plant-based diet toward upright walking/running on open terrain and more meat consumption. One consequence of the shift to a culture that included more physically active hunting was a need for evaporative cooling from sweat, which to be functional, meant an evolutionary shift toward less body hair, as evaporation from sweat-wet hair would have cooled the hair but not the skin underneath. A second consequence was darker skin. The early humans who evolved in the regions of the globe near the equator had permanent large quantities of melanin in their skin, resulting in brown/black skin tones. For people with light skin tone, exposure to UV radiation induces the synthesis of melanin causing the skin to darken, i.e., sun tanning. Either way, the pigment can protect skin by dissipating up to 99.9% of absorbed UV radiation. In this way, melanin protects skin cells from UVA and UVB radiation damage that causes photoaging and the risk of melanoma, a cancer of melanin cells. Melanin also protects against photodegradation of the vitamin folate in skin tissue and, in the eyes, preserves eye health. The dark-skinned humans who had evolved in Africa populated the rest of the world through migration some 50,000 to 80,000 years ago.

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon made of?

It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.

Why is it called epitalon?

The name derives from epithalamin, a pineal gland extract studied in the former Soviet Union. Researchers proposed that short fragments of that extract carried the biological activity of interest.

Is epitalon approved for medical use?

No major regulatory agency has approved it as a medicine. It is handled as a research chemical, and products sold under this name are not standardised drugs with defined clinical labelling.

What is epitalon made of?

It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.

Network